Pal-GHK
Palmitoyl Tripeptide-1
Pal-GHK (Palmitoyl Tripeptide-1) is a healing & recovery research compound. GHK anchored to palmitic acid for skin penetration — signals collagen and extracellular-matrix repair. The palmitoyl group sits on the free N-terminal amine that GHK uses to bind copper, so this form delivers no copper.
Pal-GHK quick facts
| Reported research dose | Topical, as directed |
| Route | Topical |
| Frequency | 1-2x Daily (topical) |
| Half-life | N/A (topical) |
| Forms | Topical |
| Evidence level | Cosmetic/topical |
The topical, skin-penetrating relative of GHK — but not of GHK-Cu: palmitoylation blocks the copper-binding site, so this is a pure signaling peptide. Collagen support for the face.
How Pal-GHK works
GHK anchored to palmitic acid for skin penetration — signals collagen and extracellular-matrix repair. The palmitoyl group sits on the free N-terminal amine that GHK uses to bind copper, so this form delivers no copper.
Proposed benefits
Collagen and skin-repair signaling for anti-aging (cosmetic).
Where to get Pal-GHK
See vetted vendors for Pal-GHK →The evidence for Pal-GHK
Graded by what exists behind each claim.
✅ Clinically validated
- Cosmetic clinical data exists — palmitoyl tripeptide-1 is one of the better-studied cosmeceutical peptides, with controlled studies reporting increased collagen and reduced wrinkle depth in topical formulations, often combined with palmitoyl tetrapeptide-7 as Matrixyl 3000.
📊 Correlative data
- Very wide cosmetic use over two decades. Reported experience is of a real but gradual effect over months, which is what a collagen-synthesis mechanism should produce.
🧪 Theoretical / extrapolated
- GHK with a palmitic acid chain attached. The lipid tail is the entire point: it makes the peptide lipophilic enough to cross the stratum corneum, which unmodified GHK does poorly.
- It signals fibroblasts to produce collagen and glycosaminoglycans. Unlike GHK-Cu it carries no copper, so it is a pure signaling peptide with none of the copper-load considerations.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pal-GHK actually does
Pal-GHK is palmitoyl tripeptide-1: palmitic acid amide-bonded to Gly-His-Lys. The Cosmetic Ingredient Review defines it as the reaction product of palmitic acid and a three-residue peptide of glycine, histidine and lysine, and it gives Gly-His-Lys as the example structure under the broader older name palmitoyl oligopeptide CIR Expert Panel (Cosmetic Ingredient Review) 2012 — so two different INCI names on two different bottles can describe the same molecule, which is worth knowing before paying twice for it.
The chemistry, computed from the sequence. Free GHK is 340.38 Da with an isoelectric point of 9.70; it carries about +1.05 units of charge at blood pH and +1.92 at the pH of the skin surface. Palmitoylation brings it to 578.79 Da.
Now the part that decides whether this ingredient means what it is sold to mean. GHK is famous because of GHK-Cu, and the copper complex has a specific architecture: computational and spectroscopic work describes copper held in a 3N1O equatorial arrangement, with a fifth, more mobile apical contact from the C-terminal carboxylate Alshammari 2020. The three nitrogens are the N-terminal amine, the deprotonated backbone amide, and the imidazole of histidine. Palmitoylation attaches the fatty acid to that N-terminal amine and turns it into a fatty amide. The anchor of the copper site is the exact atom the palmitoyl group occupies.
So the standard description — that Pal-GHK is GHK made able to cross skin — is chemically the wrong description. It is a different molecule that cannot assemble the complex GHK is famous for, and it is sold on that complex’s reputation. This site’s own card gets closer than most by saying it carries no copper; what it does not say is that the modification also removes the ability to pick copper up from the skin.
And here is the experiment that makes this matter rather than being a chemist’s quibble. GHK-Cu raised matrix metalloproteinase-2 in fibroblast conditioned medium with a matching rise in MMP-2 mRNA, and also raised the tissue inhibitors TIMP-1 and TIMP-2. In the same paper, copper ions alone reproduced the effect and the tripeptide alone did not Simeon 2000. On that read-out, the metal was doing the work. Pal-GHK is the metal-free version of a peptide whose metal-free version failed that specific test.
The counterweight, stated because it is real. Copper-free GHK is not inert on every read-out: GHK reduced TNF-alpha-driven interleukin-6 secretion in normal human dermal fibroblasts, and so did Gly-Gly-His and the copper complexes of both Gruchlik 2012. The gene-expression case for the peptide is large and is set out by the group that has worked on it for four decades Pickart 2015 Pickart 2018. What none of that literature tests is the N-palmitoylated form, which is the thing in the bottle.
The tail also does something structural. C16-GHK is one of the palmitoyl lipopeptides shown to self-assemble in water, alongside C16-KTTKS Castelletto 2013 — so the ingredient in a finished serum may be present as an aggregate rather than as free molecules, and its effective concentration is not simply the number on the specification sheet.
Cell, rodent, human — and where it stops
Cells: strong for the peptide, silent on the ingredient. The fibroblast work that this molecule borrows its reputation from used GHK or GHK-Cu, not palmitoyl-GHK: MMP-2 and TIMP induction with copper as the active partner Simeon 2000; suppression of TNF-alpha-dependent IL-6 by GHK, GGH and their copper complexes in normal human dermal fibroblasts Gruchlik 2012; and a large gene-expression literature reviewed by the peptide’s original describers Pickart 2015 Pickart 2018. Search that same literature for the palmitoylated analog and you find self-assembly physics Castelletto 2013 and market-survey appearances in commercial formulas Resende 2021. There is no published fibroblast dose-response for palmitoyl tripeptide-1 itself.
Rodents: nothing. No mouse, rat, pig or guinea-pig study of palmitoyl tripeptide-1 has been published. The animal literature belongs to GHK-Cu.
Humans: no trial isolates it. Where palmitoyl tripeptide-1 appears in a controlled study it appears inside a blend — most often paired with palmitoyl tetrapeptide-7, which has its own card in this Vault. A blend result cannot attribute anything to one component. The nearest thing to a clean human answer for the strategy is a different palmitoylated peptide: topical palmitoyl-RGD for 12 weeks in Korean women reduced photodamage and roughness scores and increased skin elasticity and dermal density over time, with type I procollagen up and MMP-1 down in human dermal fibroblasts Bae 2017. That is evidence palmitoylation-plus-topical can produce a measurable human change. It is not evidence about this peptide.
The first obstacle is the ordinary one. 578.79 Da is above the 500 Da threshold for intact stratum corneum Bos 2000, and GHK is named among the anti-wrinkle peptides whose permeability is the unaddressed problem of the field Mortazavi 2022.
The second obstacle is specific to this molecule and nobody states it. Suppose the palmitoyl group works exactly as advertised and delivers the molecule into the viable epidermis. It arrives as N-palmitoyl-GHK, and the mechanism it is sold on needs free GHK. For the delivery story to become the mechanism story, skin has to cleave a fatty amide — not an ester. Esterases are everywhere in skin and cleave esters readily; an N-acyl amide is a much harder bond, N-acylation is precisely what blocks aminopeptidase attack at a peptide’s N-terminus, and that blockade is why palmitoylated peptides survive skin homogenate better than free ones Choi 2014. The same feature that buys stability forbids the unmasking. No published study has looked for free GHK in skin after applying palmitoyl-GHK.
The arithmetic, with its assumptions on the table. Take 1 mg of palmitoyl tripeptide-1 actually applied across a face — a generous figure for a leave-on serum. That is 1.73 µmol. The viable epidermis plus papillary dermis under 400 cm² of face is roughly 400 cm² by 0.5 mm, about 20 mL of tissue. If every molecule crossed, the tissue concentration would be about 86 µM. At the 1% delivery efficiency that is generous for a peptide over 500 Da, it is 0.9 µM; at the fraction implied by a permeation study where the dermal recovery was one-fourteenth of the stratum corneum recovery Choi 2014, lower again. Micromolar is the range fibroblast work on this family uses, so the answer is not hopeless — it is marginal, and it has never been measured for this compound in a person. That is a different and more useful statement than either ‘proven’ or ‘impossible’.
Pal-GHK pharmacokinetics — how much of it actually gets in
What degrades it, and the one thing the tail genuinely buys. A free peptide N-terminus is what aminopeptidases grip. Acylating it removes the handle, which is why a palmitoylated peptide outlasts its parent in skin Choi 2014. That is a real and measurable benefit of the modification, and it is separate from the penetration claim, which is the one that gets advertised.
The barrier. 578.79 Da against a 500 Da rule of thumb Bos 2000, on a molecule whose C16 chain makes it partition happily into stratum corneum lipid and reluctantly out of it. There are zero published permeation measurements for palmitoyl tripeptide-1 in any skin model, human or animal — the numbers that exist in this cohort belong to palmitoyl-KTTKS.
The copper accounting. A product built on this ingredient delivers 0 µg of copper, because there is none in the molecule. That matters twice: it is the reason this ingredient carries no copper-load question at all, and it is the reason a product listing palmitoyl tripeptide-1 and calling itself a copper peptide serum is mislabelled. Serum copper and ceruloplasmin have no route to move on this compound — not because the dose is small, but because the dose is zero.
Route. Topical only. There is no oral, subcutaneous or intravenous pharmacokinetic study of palmitoyl tripeptide-1 in any species, so half-life, clearance and bioavailability are not small numbers here — they are absent numbers. What can be bounded is the mass: a serum applied at 2 mg/cm² over 400 cm² of face puts 800 mg of product on the skin, and the peptide fraction of that is parts per million to parts per ten thousand, so the applied peptide is measured in tens to hundreds of micrograms per application.
What would have to be true, and how you would know it was not
What to watch. Dermal density and skin elasticity, measured — a cutometer reading and a high-frequency ultrasound density measurement from a marked spot on the cheek, or failing equipment, a fixed-lighting photograph at a fixed distance with the same lens at weeks 0, 6 and 12. Those are the endpoints that moved in the closest comparable human study of a palmitoylated peptide Bae 2017, so they are the endpoints worth copying.
How long before it means anything. Twelve weeks. Dermal matrix is slow, and the comparable trial took that long to separate from baseline.
What will fool you. The blue. GHK-Cu products are blue because of the copper complex; palmitoyl tripeptide-1 products are not, and people read the color as potency in both directions. The second trap is the blend: this ingredient is almost always sold beside palmitoyl tetrapeptide-7, and neither of you can attribute an effect to one of them.
Prediction 1, and it cuts against the product. Serum copper and ceruloplasmin will not move, at any use level, for any duration. There is no copper in the molecule and no proposed route by which it changes copper handling. Anybody selling this as a copper peptide is making a claim that a single blood draw refutes, and this site has marker pages for both tests.
Prediction 2, the one that would decide the mechanism. Apply palmitoyl tripeptide-1 to one forearm and GHK-Cu at equal molarity to the other for 8 weeks, then biopsy or tape-strip and assay for free GHK. If free GHK is not recoverable on the palmitoylated side, the delivery claim and the mechanism claim cannot both be true — because the copper site is occupied by the very group that got it through Alshammari 2020. This is the experiment this page exists to point at.
Prediction 3, and it is uncomfortable for the category. Because the metal did the work in the one experiment that separated them Simeon 2000, a copper-free analog should underperform GHK-Cu on matrix remodeling read-outs. If a split-face comparison shows them equal, then either the MMP-2 result does not generalize or the visible cosmetic effect is not coming from the mechanism either product claims. Both of those are more interesting than a win.
What nobody has tested yet
1. Nobody has asked whether skin can take the palmitoyl group off. This is the single question the ingredient stands or falls on, it needs one skin-homogenate incubation and a mass spectrometer looking for the 340.38 Da fragment, and in twenty years of the ingredient being on the market it has not been published.
2. Nobody has measured whether palmitoyl-GHK binds copper at all. The parent’s copper geometry is worked out to the level of individual coordinating atoms Alshammari 2020. Whether the N-acylated version retains any affinity, perhaps through the imidazole and a different set of donors, is a UV-visible and electron paramagnetic resonance afternoon. A related conjugate makes the question live rather than rhetorical: biotinylated GHK does still coordinate copper(II) Tosto 2023, so a modified GHK is not automatically a dead chelator, and which modifications kill the site has never been mapped.
3. Nobody has run the three-way comparison. GHK, GHK-Cu and palmitoyl-GHK, equal molarity, same fibroblasts, same read-outs — collagen, MMP-2, TIMP-1, IL-6. Two of the three arms already have published data Simeon 2000 Gruchlik 2012; only the arm in everybody’s bathroom cabinet is missing.
4. No human trial has ever isolated this ingredient. Every controlled cosmetic study containing it also contains something else. A single-ingredient split-face study at a stated peptide concentration would be the first.
5. Nobody has looked at the MMP/TIMP balance in living human skin under any of these peptides. The in-vitro finding is that this family raises both a collagenase and its inhibitors Simeon 2000, which is remodeling rather than accumulation. Suction blister fluid or a microbiopsy assayed for MMP-2 and TIMP-1 before and after a course would tell you which way the balance actually tips in a person, and would apply to the whole category rather than to one bottle.
Pal-GHK — its own safety story, not its class's
The class block on this page is written for injected repair peptides. Three things here are specific to this molecule, and the first one is a reason to prefer it rather than to avoid it.
Vitamin C, and why this is the copper-peptide card where it does not apply. Ascorbate reduces copper(II) to copper(I), and copper(I) with oxygen generates reactive species — the pairing is used as a laboratory assay in exactly this peptide family, where copper-induced ascorbate oxidation is the read-out for whether a GHK conjugate is protective or not Tosto 2023. That is a live chemical interaction for any product carrying an actual copper complex. Palmitoyl tripeptide-1 carries no copper, so layering it under an L-ascorbic acid serum has no metal-redox problem at all. This is a genuine, mechanism-derived advantage over GHK-Cu and it is not on any product page.
The finding that belongs in a safety section and is never put there. This family raises matrix metalloproteinase-2 — an enzyme whose job is degrading matrix — alongside its inhibitors TIMP-1 and TIMP-2 Simeon 2000. That is the signature of a remodeling agent, not an accumulating one. Practically: expect reorganization of what is there rather than net deposition, do not stack it with several other remodeling actives at once on skin that is already inflamed, and understand that the same balance is why results in this category are slow and modest rather than dramatic.
Acids and retinoids, stated at the right level of confidence. The histidine imidazole has a side-chain pKa near 6.5 on this site’s own chemistry module, so a glycolic or ascorbic step at pH 3.5 leaves it fully protonated and the peptide more cationic. For a copper complex that would matter; for this metal-free amide it mostly changes solubility and skin binding, not activity. The real reason not to layer it directly on top of a retinoid is that two irritants in one layer produce one irritation, and you will not know which caused it. There is no published interaction study for this ingredient with any retinoid or any acid, and saying so is more useful than inventing a rule.
What zero reported adverse events means. Palmitoyl tripeptide-1 has been in wide cosmetic use for two decades with no signal, and it appears in ingredient-safety surveys of marketed products without flags Resende 2021 CIR Expert Panel (Cosmetic Ingredient Review) 2012. That is meaningful reassurance about irritation and sensitization at cosmetic concentrations. It is not evidence of efficacy, and the two get conflated on every page that sells it.
Sources read for this page
- CIR Expert Panel (Cosmetic Ingredient Review). Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics (scientific literature review). Cosmetic Ingredient Review 2012
- Alshammari N, Platts JA. Theoretical study of copper binding to GHK peptide. Comput Biol Chem 2020 · PMID 32371360
- Simeon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci 2000 · PMID 11045606
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm 2012 · PMID 23285694
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018 · PMID 29986520
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015 · PMID 26236730
- Castelletto V, Hamley IW, Perez J, Abezgauz L, Danino D. Self-assembly of palmitoyl lipopeptides used in skin care products. Langmuir 2013 · PMID 23822110
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 · PMID 10839713
- Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci 2022 · PMID 35302659
- Choi YL, Park EK, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul) 2014 · PMID 25143811
- Bae JS, Lee SH, Kim JE. Topical application of palmitoyl-RGD reduces human facial wrinkle formation in Korean women. Arch Dermatol Res 2017 · PMID 28752204
- Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel) 2021 · PMID 34451799
- Tosto R, Bellia F, Pandini G, Naletova I, Attanasio F, Zimbone S, Grasso G. New Biotinylated GHK and Related Copper(II) Complex: Antioxidant and Antiglycant Properties In Vitro against Neurodegenerative Disorders. Molecules 2023 · PMID 37764500
Pal-GHK — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Pal-GHK — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
Applied topically, this has no systemic exposure worth speaking of — so there is nothing to interact with anything you take, and no blood marker it could move. That is the honest answer rather than an empty section. The real interactions for a topical are layering ones: what you put on before and after it, and at what pH.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Pal-GHK in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pal-GHK
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pal-GHK — frequently asked questions
What is Pal-GHK?
Pal-GHK (Palmitoyl Tripeptide-1) is a healing & recovery research compound. GHK anchored to palmitic acid for skin penetration — signals collagen and extracellular-matrix repair. The palmitoyl group sits on the free N-terminal amine that GHK uses to bind copper, so this form delivers no copper.
Is the full Pal-GHK protocol on this page?
The reported research dose is on this page, along with how Pal-GHK works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Pal-GHK?
Pal-GHK has an approximate half-life of N/A (topical), which is part of what determines how often it's dosed.
What's the evidence behind Pal-GHK?
Current evidence level: Cosmetic/topical. Pal-GHK is offered for research purposes only and is not an approved medicine.
What Pal-GHK is used for
Pal-GHK appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.